Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
12 March 2018 Photo Leonie Bolleurs
Second triumph for young pollution and pharmaceutical researcher
Emmie Chiyindiko, winner of Famelab.
“I am grateful to be reaping the benefits of stepping out of my comfort zone. By facing the unfamiliar, that challenge will allow me to see what great things I am capable of,” said Emmie Chiyindiko, winner of Famelab 2018.

With FameLab, the world’s leading science communication competition, participants have just three minutes to win over the judges and crowd with a scientific talk that excels in content, clarity and charisma. Contestants from around the world participate, armed only with their wits and a few props.

Emmie won the Postgraduate School’s Three-Minute-Thesis competition for master’s level in 2017.

She said: “My research is based on the synthesis and characterisation of a series of unique metal complexes.” These complexes are used both as active pharmaceutical ingredients and cosmetic additives to reduce the detrimental effects of UV radiation on the skin. They are incorporated into anti-ulcer, gastro protective drugs, anti-asthmatic, lung disease drugs, with anti-cancer and anti-diabetic agents,” she said.

With her research she can also monitor air pollution. Formaldehyde is a known toxin to human health. “Using metal complexes, I am able to monitor the production of formaldehyde and consequently come up with exposure prevention methods,” said Emmie.

She believes that it is okay to not ”fit in“. “Mannerisms such as your quirks make you different and distinctive. Live your life intentionally, imprint your personal mark on this universe and always choose faith over fear.”

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept